Technology Behind
INNOVA3® R-ALA Technology enhances R-ALA at the molecular level, improving its stability, absorption, and efficacy. Powered by LipoXTEND® Technology, it ensures protection during digestion, sustained release, and prolonged mitochondrial support, delivering unmatched bioavailability and lasting benefits.
The MitoDrone Ligand (MTTP with TPP) incorporates affinity peptides to specifically target cardiac mitochondria while avoiding expulsion by efflux mechanisms.
Encapsulation within D-α-Tocopherol Polyethylene Glycol Succinate (Vitamin E TPGS) micelles further enhances solubility and permeability of R-ALA. LipoXTEND®’s engineered Add-On Technology forms a modified polymeric surface that creates a bilayer phospholipid vesicle with a protective wax shell, safeguarding and enhancing the micelle-encapsulated R-ALA for maximum stability and performance.
Key Challenges
INNOVA3® increases R-ALA’s melting point, making it heat-stable and resistant to oxidation, degradation, or polymerization.
Encapsulation within Vitamin E TPGS micelles enhances water solubility and cellular uptake, delivering superior bioavailability and sustained effectiveness.
LipoXTEND® liposomal delivery ensures 60–80% absorption by protecting R-ALA from breakdown in the digestive system.
Reduces gastrointestinal irritation and slows metabolism, allowing for smoother digestion and extended therapeutic effect.
INNOVA® Alpha Lipoic Acid Advanced Formulation
INNOVA® Alpha Lipoic Acid Advanced Formulations:
(1) Pure Alpha Lipoic Acid (>98%) is engineered into an amoprphous state to enhance solubility, stability and absorption.
(2) Its structure is designed to resist degradation from UV light and heat, overcoming photodegradable limitations of traditional CoQ10
INNOVA3® Alpha Lipoic Acid Targeted Delivery & Protection Technologies
Leveraging the New Advancements with the INNOVA3® Alpha Lipoic Acid:
- INNOVA® Alpha Lipoic Acid: Ultra-pure form of Alpha Lipoic Acid engineered with an amorphous-state surface with isotropic characteristics, for superior solubility, stability and UV\heat resistance
- MitoDrone® Technology: Specifically engineered peptides system that recognize and bind to mitochondrial surface receptors, enabling receptor-mediated endocytosis. By using affinity peptides, it ensures that INNOVA® Alpha Lipoic Acid penetrating the cellular barriers and are actively taken up by mitochondria.
- Vitamin E TPGS Micelles: Alpha Lipoic Acid is conjugated and encapsulated within Vitamin E TPGS (D-tocopheryl polyethylene glycol succinate) Micelle in the aqueous core, to enhance solubility and bioavailability.
- LipoXTEND® Polymeric Surface Add-On Technology: Modified polymeric surface liposomes provides protection against enzymatic degradation and ensures prolonged circulation.
Mechanism of Action
1- Converts Alpha Lipoic Acid into ultra-pure, heat-resistant form to improve stability.
2- Targets mitochondria via affinity peptides (TPP, MTP) for receptor-mediated endocytosis.
3- Encapsulating Alpha Lipoic Acid in Vitamin E TPGS micelle in the aqueous core for enhanced solubility and absorption
4- Liposomal and polymeric surface modifications protect payload during digestion and improve membrane penetration.
5- Sustained release maintains steady levels, reducing dosing frequency.
Advanced Stability with INNOVA3® Alpha Lipoic Acid
Thermostable, UV-resistant amorphous structure ensures 2x longer shelf life, 90% less degradation, and consistent potency even in harsh or challenging conditions.
Precision Targeting with MitoDrone®
TPP peptides and Dual-Ligands target Alpha Lipoic Acid to cardiac mitochondria, increasing Alpha Lipoic Acid 5x, ATP 300%, enhancing uptake and reducing efflux by 70%
Enhanced Absorption with LipoXTEND® Delivery
Liposomal encapsulation with polymeric wax shell protects Alpha Lipoic Acid, enabling 4x bioavailability, 85% absorption, and extended plasma retention for 6–8 hours.
Pharmacokinetics
INNOVA3® Alpha Lipoic Acid advanced Targeting Technologies and LipoXTEND® Polymeric Surface Technologies to dramatically improve the pharmacokinetics of active ingredients delivered to the heart tissues
-
Peak Plasma Concentration: INNOVA3® R-ALA reached 4.8 mg/L vs. 1.6 mg/L with standard R-ALA.
-
Time to Peak (Tmax): INNOVA3® peaked at 8 hours, while standard R-ALA peaked at 2 hours.
-
Plasma Half-Life: INNOVA3® had a half-life of 8–10 hours compared to 1–2 hours for standard R-ALA.
-
Bioavailability: INNOVA3® R-ALA showed 4× higher bioavailability than standard R-ALA.
No chart data available for this technology.